Analysts See $0.43 EPS for Neurocrine Biosciences, Inc. (NBIX)

October 14, 2018 - By Adrian Mccoy

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment increased to 1.21 in Q2 2018. Its up 0.05, from 1.16 in 2018Q1. It improved, as 23 investors sold Neurocrine Biosciences, Inc. shares while 78 reduced holdings. 43 funds opened positions while 79 raised stakes. 91.33 million shares or 1.85% more from 89.67 million shares in 2018Q1 were reported.
Woodstock reported 16,578 shares. 1.16M were reported by Alliancebernstein L P. Envestnet Asset Mgmt has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 497 shares. Healthcor Mngmt Lp holds 793,955 shares or 2.48% of its portfolio. Frontier Mngmt Company has invested 0.45% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Mirae Asset Glob Investments reported 85,594 shares. Proshare Ltd Company reported 39,920 shares. Profund Advsr Limited reported 0.11% stake. Chicago Equity Prns Lc accumulated 8,265 shares. Advisory owns 3,541 shares. Asset Mngmt has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Pictet Asset Limited holds 0.22% or 916,529 shares in its portfolio. Moneta Gru Advisors Limited Liability Corporation has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Mutual Of America Cap Lc owns 0.16% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 107,374 shares. Aperio Gp Limited Liability, California-based fund reported 28,705 shares.

Since May 1, 2018, it had 0 insider buys, and 7 insider sales for $25.40 million activity. The insider LYONS GARY A sold 15,000 shares worth $1.49 million. 23,000 shares were sold by Grigoriadis Dimitri E., worth $2.42M. Shares for $415,625 were sold by Nevinny Corinne H. 10,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $984,420 were sold by SHERWIN STEPHEN A. GORMAN KEVIN CHARLES had sold 126,832 shares worth $10.24 million.

Analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $0.43 EPS on November, 7.They anticipate $0.56 EPS change or 430.77 % from last quarter’s $-0.13 EPS. NBIX’s profit would be $38.90M giving it 64.81 P/E if the $0.43 EPS is correct. After having $-0.07 EPS previously, Neurocrine Biosciences, Inc.’s analysts see -714.29 % EPS growth. The stock increased 3.16% or $3.42 during the last trading session, reaching $111.48. About 655,541 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 111.53% since October 14, 2017 and is uptrending. It has outperformed by 95.91% the S&P500.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 8 analysts covering Neurocrine Biosciences (NASDAQ:NBIX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosciences had 10 analyst reports since May 1, 2018 according to SRatingsIntel. JP Morgan maintained the shares of NBIX in report on Tuesday, May 1 with “Overweight” rating. On Wednesday, August 1 the stock rating was maintained by Barclays Capital with “Overweight”. H.C. Wainwright maintained it with “Buy” rating and $13900 target in Tuesday, May 1 report. The rating was maintained by Robert W. Baird on Tuesday, May 1 with “Outperform”. The firm has “Buy” rating given on Tuesday, May 1 by Deutsche Bank. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, September 20. As per Wednesday, July 25, the company rating was maintained by Robert W. Baird.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $10.09 billion. The company??s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women??s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson??s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Another recent and important Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news was published by which published an article titled: “Neurocrine: Time To Reduce?” on October 05, 2018.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News